Home  >  Product Launches
you can get e-magazine links on WhatsApp.Click here
Product Launches
+ Font Resize -

Axio Biosolutions launches innovative wound care dressing made of chitosan, MaxioCel

Our Bureau, Bengaluru
Tuesday, February 12, 2019, 14:10 Hrs  [IST]

Introducing the latest innovation in wound care, Axio Biosolutions has launched MaxioCel, a next generation wound care dressing made of chitosan. Dr. V. S. Bedi, director and chairman, Vascular and Endovascular Department, Sir Gangaram Hospital, launched MaxioCel at the ‘Endovascular Live 2019’ at Pullman Novotel, New Delhi.

In 2018 Axio had become the first Indian company to get US FDA clearance for its innovative hemostatic dressing - Axiostat. With MaxioCel, the next generation chitosan-based advance wound care product range, Axio is poised to further disrupt the wound care market. The ‘first of its kind’ product is expected to provide comfort and faster healing to patients suffering from chronic wounds, such as pressure ulcers, diabetic foot ulcers, venous leg ulcers, cavity wounds, skin abrasions, donor sites and post-operative surgical wounds, to name some.

Unique, 360-degree advanced wound management solution, MaxioCel was launched before a rapt audience of over 300 renowned vascular and endovascular surgeons, interventional radiologists, interventional cardiologists, podiatrists and general surgeons at ‘Endovascular Live 2019’. A paper was presented by Dr. Srujal Shah on experience of using MaxioCel. The presentation mentioned various cases done using MaxioCel range of products – Venous ulcers, diabetic foot ulcers and other complex wounds.

Commenting on the product launch, Dr. Srujal Shah (M. Ch.), Vascular & Endovascular Surgeon, IndoVasc Hospital, said, “There is a colossal increase in the number of patients suffering from chronic wounds. However, there are no products in wound care management that provide substantial relief from the high levels of discomfort and pain endured by patients. MaxioCel range of advanced chitosan dressings have the potential to address this gap and be a true game changer. The medical fraternity needs to embrace technological innovations happening in advance wound care management space in order to improve the quality of life of patients with chronic wounds.”

Leo Mavely, CEO, Axio Biosolutions, further added, “With the latest addition of MaxioCel to our product portfolio, we now have a complete range of innovative products spanning pre-hospital, intra-operative and post-operative clinical needs. India is becoming a world diabetic capital with millions of patients needing advanced wound care products every year. MaxioCel fulfills a large gap in the market with its combined hemostatic, pain management and scar improvement properties. We are proud to bring this product as an Indian innovation in wound care for the world market.

Axio Biosolutions is a medtech company with focus on biomaterials. Its first product range Axiostat is a US FDA and CE approved product that stops bleeding instantly.


Post Your commentsPOST YOUR COMMENT
* Name :     
* Email :    
  Website :  
Anupam Saxena Apr 10, 2019 9:15 AM
Copyright © 2016 Saffron Media Pvt. Ltd |